Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
158
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Ongoing Diabetes Study Program to Examine its Patented DehydraTECH(TM) Technology with Launch of Human and Animal Studies for Oral GLP-1 Drugs

- Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
- The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
- Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
- These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://nnw.fm/7GWH3 ).

The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience reduced cravings for alcohol, nicotine, and opioids while taking the drugs, with other trials showing the reduced build-up of proteins amyloid and tau in the brain, both thought to be partly responsible for Alzheimer’s.

Despite their overall potential, GLP-1 drugs have many side effects, ranging from mild ones, such as nausea and vomiting, to more serious ones, such as reduced bone density and muscle loss. Some of the more severe side effects have been reported when the drugs are taken in oral form, which has prompted researchers and medical practitioners to treat patients with lower oral doses. Given the overall nature of GLP-1 drugs to have low oral bioavailability, Lexaria, through its DehydraTECH technology, looks to address that, ultimately improving the drug’s pharmacokinetic (“PK”) performance.

In the recently completed DIAB-A22-1 diabetes study, Lexaria demonstrated an almost three-fold improvement in drug delivery into the blood compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study. With such results in this and five other human clinical studies, Lexaria has proven severally that its technology can significantly improve the PK performance of many orally administered drugs into the bloodstream. Its applications have ranged from cannabinoids, estradiol, PDE-5 Inhibitors, and certain antiviral drugs. The company is optimistic about the technology’s application, GLP-1, and its potential to improve its bioavailability.

The animal and human clinical studies on GLP-1 will be a logical progression to Lexaria’s efforts to explore DehydraTECH in the potential treatment of diabetes, which kicked off in 2022. In its pre-clinical study DIAB-A22-1, DehydraTECH-CBD has yielded a 19.9% lowered blood glucose level, a 7% lowered overall body weight sustained over eight weeks, increased locomotor activity, lowered triglyceride levels by more than 25%, and lowered blood urea nitrogen levels by 27.9%. Given its intention to study weight loss and diabetes control in a human population using DehydraTECH, as announced on August 2, 2023, the GLP-1 studies come at the opportune time, facilitating this specific objective.

Program design for the GLP-1 study has already commenced, and initial study work is set to begin as soon as possible. This ambitious step affirms Lexaria’s commitment to creating shareholder value and advancing its technology to become a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Lexaria Bioscience Corp. (LEXX) Stock Research Links

LEXX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tronox Pushes Back on Creditor Restructuring Chatter Firmly

Updated Category News Views 115

A Creditor Rumor Is Not a Restructuring Plan Two creditor groups hiring law firms can make a stock chart look like it stepped on a rake, but it is not the same thing as a debt workout. That distinction is the whole point of Tronox Holdings' November 18 update. A November 17 Wall Street Journal report said two groups of creditors had retained firms described as...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 106

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 127

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading
BVM's Brookfield Headquarters Move Tests Growth Ambition

Updated Category News Views 119

A bigger office is rarely the exciting part of a growth story, yet it can reveal whether the machinery underneath is actually running hot. Best Version Media has moved its headquarters from Janacek Court to 15800 W. Bluemound Road, Suite 400, in Brookfield, Wisconsin, citing room for recent hires, future recruitment and closer collaboration across its print and digital...

Continue Reading
Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Trip.com Sets December 1 Date for Third-Quarter Results

Updated Category News Views 17

December’s first after-hours session will put Trip.com Group back under the market’s microscope, whether anybody is ready or not. The company says it will report results for the three months ended September 30, 2026 after the U.S. market closes on Tuesday, December 1. That is the whole hard-news payload for now: a reporting date, a call time, and no numbers to get...

Continue Reading
Tongwei's 846 MW Romania Deal Tests Solar Supply Scale

Updated Category News Views 5

Eight hundred forty-six megawatts of panels do not quietly roll out the factory gate. Tongwei’s supply agreement with Rezolv Energy for Romania’s Dama Solar project is a hefty piece of utility-scale solar business, and the first truckload has already left Tongwei’s Nantong facility. That matters more than another polished signing-ceremony photo: equipment is moving,...

Continue Reading
SHIFTAIon Puts Governance at Center of AI Migration

Updated Category News Views 69

Legacy code is where grand AI promises usually go to get mugged by reality. ACL Digital’s new SHIFTAIon platform is taking a sensible swing at that ugly problem: not merely generating code faster, but putting discovery, architecture decisions, testing, security checks, reviewer signoffs, and reporting into one controlled modernization process. That distinction matters....

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 26

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 12

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Share Buybacks and Voting Rights Dynamics

Updated Category News Views 130

Overview of Share Buybacks In recent financial news, Octopus AIM VCT plc has engaged in a strategic move by purchasing its own shares. This action is often a signal of confidence in the company's future and an investment in its own value. Details of the Transaction The company has recently announced the acquisition of 590,908 ordinary shares at a price of 47.27p each....

Continue Reading
Kojamo's Financial Report Highlights: Growth and Outlook

Updated Category News Views 186

Overview of Kojamo plc's Financial Performance Kojamo plc has recently published its financial report, highlighting significant changes and developments in their occupancy rates and revenues for the first half of the fiscal year. This report is particularly important for investors and stakeholders keen on understanding the company's financial health. Financial Highlights...

Continue Reading
Silicom Ltd. Partners with U.S. Firm for Edge Networking Growth

Updated Category News Views 167

Silicom Ltd. Partners with Provider for Edge Networking Solutions - $1 million annual run rate with potential for a significant multi-million-dollar scale-up - Silicom Ltd. (NASDAQ: SILC), a recognized leader in networking and data infrastructure solutions, has announced an exciting collaboration with a U.S.-based provider specializing in Edge networking solutions...

Continue Reading
Understanding the Ongoing Securities Case Against Five Below, Inc.

Updated Category News Views 120

Overview of the Class Action Lawsuit Against Five Below, Inc. As an investor, it's essential to stay informed about your rights, especially with ongoing legal matters. Currently, a notable class action lawsuit is underway involving Five Below, Inc. (NASDAQ: FIVE), which is particularly relevant for its shareholders. Class Period Details The allegations pertain to the time...

Continue Reading
Worthington Enterprises to Boost Portfolio with LSI Group Buyout

Updated Category News Views 169

Worthington Enterprises Expands Its Portfolio with Major Acquisition Worthington Enterprises Inc. (NYSE: WOR), renowned for its innovative designs and manufacturing prowess, has officially announced its intent to acquire LSI Group, LLC. This major acquisition positions Worthington Enterprises to enhance its offerings and market presence in the metal roofing sector....

Continue Reading